Division of Host Defense, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
J Inflamm Res. 2010;3:33-44. doi: 10.2147/jir.s6375. Epub 2010 Jun 18.
Until recently, autoimmune diseases had been categorized as either Th1- or Th2-mediated diseases. However, the discovery of a novel subset of helper T cells producing interleukin (IL)-17, ie, Th17 cells, changed this paradigm. Currently, IL-17 and Th17 cells are implicated in many autoimmune diseases, such as rheumatoid arthritis, psoriasis, multiple sclerosis, and inflammatory bowel diseases. Such conclusions were initially drawn from observations in animal models of autoimmune diseases, and accumulating data from clinical research also support the involvement of IL-17 in human diseases as well. Reagents targeting Th17-related molecules have been under clinical investigation for some diseases but have not always been effective in controlling disease activity. Consistent with this, it has become evident that there are substantial differences in the development of Th17 cells and in the way they function in autoimmune diseases between humans and experimental animals. Thus, further investigation is needed before we can draw any conclusions about the importance of IL-17 and Th17 cells in human autoimmune diseases.
直到最近,自身免疫性疾病一直被分为 Th1 或 Th2 介导的疾病。然而,新型辅助性 T 细胞亚群——产生白细胞介素(IL)-17 的 Th17 细胞的发现改变了这一模式。目前,IL-17 和 Th17 细胞与许多自身免疫性疾病有关,如类风湿关节炎、银屑病、多发性硬化症和炎症性肠病。这些结论最初是从自身免疫性疾病的动物模型观察中得出的,临床研究积累的数据也支持 IL-17 参与人类疾病。针对 Th17 相关分子的试剂正在一些疾病的临床研究中,但并不总是能有效控制疾病活动。与此一致的是,在 Th17 细胞的发展以及它们在人类和实验动物自身免疫性疾病中的作用方式方面,存在着显著的差异。因此,在我们对 IL-17 和 Th17 细胞在人类自身免疫性疾病中的重要性得出任何结论之前,还需要进一步的研究。